Protocol T Comparing Three DME Agents Released

Protocol T Comparing Three DME Agents Released A major government-sponsored study shows that intravitreous aflibercept (Eylea; Regeneron), bevacizumab (Avastin; Genentech), and ranibizumab (Lucentis; Genentech) were effective and safe treatments for diabetic macular edema (DME), however, the relative effect correlat...